TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients

NCT06455917 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer
Lung Cancer (NSCLC)

Interventions

DRUG: TILs（Tumor Infiltrating Lymphocytes）

Sponsor

University Hospital, Basel, Switzerland